Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK’s investigational BCMA antibody-drug conjugate receives Breakthrough Therapy Designation from US FDA for relapsed and refractory multiple myeloma
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that it has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for GSK2857916 monothe...
Read more -
GSK study demonstrates superiority of Anoro Ellipta to Stiolto Respimat in improving lung function in chronic obstructive pulmonary disease
GlaxoSmithKline plc and Innoviva, Inc. today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist
Read more -
ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV
ViiV Healthcare, today announced results from the phase III BRIGHTE study of fostemsavir in heavily treatment-experienced (HTE) patients with HIV-1 infection.
Read more -
Public-private consortium aims to cut preclinical cancer drug discovery from six years to just one
Lawrence Livermore National Laboratory, Frederick National Laboratory for Cancer Research, GSK, and University of California San Francisco will combine vast data stores, superco...
Read more -
GSK delivers Q3 sales of £7.8 billion, +4% AER, +2% CER
Total EPS 24.8p, +49% AER, +46% CER; Adjusted EPS 32.5p, +3% AER, flat CER
Read more -
CDC’s Advisory Committee on Immunization Practices recommends Shingrix as the preferred vaccine for the prevention of shingles for adults aged 50 and up
Committee recommends immunization for up to 62 million additional adults in the US
Read more -
Shingrix approved in the US for prevention of shingles in adults aged 50 and over
Pooled clinical trial results showed > 90 percent efficacy across all age groups
Read more -
GSK receives World Health Organization Prequalification for Synflorix pneumococcal vaccine four-dose vial
The World Health Organization (WHO) has awarded prequalification for the new four-dose vial presentation of Synflorix pneumococcal vaccine targeted mainly for countries that rec...
Read more -
GSK announces first approval of Shingrix in Canada
The only shingles vaccine to achieve ≥90% efficacy in adults aged 50 and over
Read more -
GSK receives approval for Benlysta in Japan for the treatment of systemic lupus erythematosus
GSK announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Benlysta (belimumab) for the treatment of adult patients with systemic lupus ery...
Read more -
GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations
Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD
Read more -
Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler trip...
Read more -
Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD
EMA CHMP issues positive opinion for Trelegy Ellipta.
Read more -
GSK receives CHMP positive opinion for self-injectable formulation of Benlysta for systemic lupus erythematosus
GSK today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion
Read more -
FDA Advisory Committee votes unanimously for Shingrix (HZ/su) in the US for prevention of herpes zoster (shingles) in adults ages 50 and over
GlaxoSmithKline plc [LSE/NYSE: GSK] announced today that the Vaccines and Related Biological Products Advisory Committee (VRBPAC) of the US Food and Drug Administration (FDA) vo...
Read more -
GSK announces phase III results published in NEJM of mepolizumab in patients with eosinophilic COPD at risk of exacerbations
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the publication of full results from the phase III studies for mepolizumab in chronic obstructive pulmonary disease (COPD).
Read more -
Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study.
Read more -
GSK exercises option on phase I/II NY-ESO T-cell therapy (GSK3377794)
Today GSK announced that it has exercised the option to obtain an exclusive global license from Adaptimmune for an investigational SPEAR T-cell receptor therapy targeting NY-ESO...
Read more -
GSK presents respiratory data from pipeline to clinical practice at ERS
45 abstracts will be shared adding to clinical and scientific knowledge about current and future treatments for patients with respiratory diseases
Read more -
GSK responds to UK Life Sciences Industrial Strategy
Read our response to the UK Life Sciences Industrial Strategy.
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday healthcare products to medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
